Other languages Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
109.5 ^USD	+1.89%		-0.44%	-11.01%

Apr. 02	Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	MT
Apr. 02	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	Apr. 02
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	Apr. 02
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours	Feb. 28
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024	Feb. 28
Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28
Jazz Pharmaceuticals Announces Board Changes	Feb. 27
Jazz Pharmaceuticals Names Philip Johnson as Chief Financial Officer	Feb. 21
Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024	Feb. 21
Las últimas operaciones de los gestores estrella	Feb. 19
De recentste transacties van de sterbeheerders	Feb. 17
Les dernières transactions des gérants stars	Feb. 15
Jazz Pharmaceuticals to Acquire Redx Pharma's KRAS Inhibitor Program	Feb. 07
Barratt and Smurfit Kappa bookend FTSE 100	Feb. 07
RedX Pharma to Sell Kirsten Rat Sarcoma Virus Inhibitor Program to Jazz Pharmaceuticals	Feb. 07
Redx Pharma shares skyrocket on deal to sell inhibitor program	Feb. 07
AIM WINNERS & LOSERS: Verditek falls on cash shell plans	Feb. 07
Jazz Pharmaceuticals Phase 2 Study of Post-Traumatic Stress Disorder Fails to Meet Primary, Secondary Endpoints	Dec. 21
Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial	Dec. 21
Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023	Dec. 15
Jazz Pharmaceuticals Says Phase 2a Data of Zanidatamab Shows Progression-Free Survival of 67% in Breast Cancer Patients	Dec. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Other languages

Filters